Can Sterile Consumables Test Reports Be Reused for Overseas Registration?

When registering sterile consumables overseas, whether test reports can be reused depends on the target country or region's regulatory requirements, product risk classification, applicable testing standards, and whether the issuing laboratory is recognized. Companies cannot directly submit NMPA, CE, or FDA test reports to all overseas regulatory authorities. They should first confirm whether the product falls under medical device regulation in the target market, determine classification and registration pathway, and then assess the transferability of existing reports on physicochemical performance, biocompatibility, microbiological validation, and sterilization validation.

Key Summary

For GHWP member countries and markets in Southeast Asia, the Middle East, and Latin America, it is usually necessary to build a core technical documentation library and conduct standard comparisons, supplementary testing, or re-issuance of reports to address local differences. Attention must also be paid to report validity periods, sample batch information, original records, and whether the issuing laboratory holds ISO 17025, GLP, or MDSAP qualifications and is within the recognized scope of the target country. Common risks include local non-acceptance of testing standards, missing recognition marks on reports, the need to re-localize labels and instructions, unclear agent qualifications, and unfulfilled post-market maintenance obligations. Companies should proactively map gaps between existing reports and target country requirements, create supplementary testing plans, and engage local agents or authorized representatives to manage submissions and subsequent changes, thereby reducing duplicate documentation and deficiency risks.

Applicable Scenarios and Core Issues

Sterile consumables typically include sterile syringes, infusion sets, puncture needles, surgical sutures, sterile dressings, and catheter-type products. These products often require extensive test reports before entering overseas markets. Many companies already hold NMPA registration test reports, test reports from CE technical files, FDA 510(k) supporting reports, or internal validation reports under ISO 13485, and therefore wish to directly reuse these materials in new overseas registrations.

However, “can it be reused” is not a simple yes or no. It must be assessed in conjunction with the target country's medical device regulations, product risk class, technical standard differences, issuing laboratory qualifications, and registration submission requirements. A test report that is acceptable in China may not be directly accepted in Southeast Asia, the Middle East, or Latin America.

The core questions are: whether the regulator recognizes the standards underlying the original report; whether reports issued by third-party laboratories are accepted; whether the report must be issued by a laboratory recognized by the target country or holding specific qualifications; and whether the data in the report is still within its validity period and matches the product intended for registration.

Companies need to strategically distinguish between “referable scientific data” and “submittable regulatory documents.” The former can significantly reduce duplicate testing, while the latter must meet the specific form and substance requirements of the target market. Therefore, the target country and product classification must be clarified at project initiation; otherwise, reports may become invalid, registration timelines may be extended, and correction costs may increase.

Registration Judgment Logic

To determine whether sterile consumable test reports can be reused, we recommend the following logical sequence.

Step 1: Confirm Regulatory Scope

Confirm whether the target country regulates the product as a medical device. Some consumables may fall under pharmaceuticals, disinfectants, or general consumer products, and the regulatory framework and test report recognition logic will differ.

Step 2: Determine Risk Class and Registration Pathway

For example, ASEAN countries generally classify medical devices into Class A, B, C, or D. Different classes have different levels of review stringency and test report requirements. High-risk implantable or long-term contact sterile consumables often require more clinical evaluation and stricter biocompatibility data.

Step 3: Identify Applicant and Local Representative

Most countries require foreign manufacturers to appoint a local agent or authorized representative. The registration certificate is usually held or co-maintained by the local agent. The manufacturer information on test reports must match the registration applicant. If the address or name changes, reports may need to be updated.

Step 4: Assess Differences in Standards

Compare the product standards, test methods, acceptance criteria, and sample information item by item. For tests such as sterility, bacterial endotoxins, particulate contamination, and biocompatibility, different countries may adopt ISO, EN, USP, EP, or national pharmacopeia methods, and limits may differ.

Step 5: Verify Laboratory Qualification

Many countries accept test reports from laboratories accredited to ISO 17025, but some countries only accept reports from designated local laboratories or globally recognized notified bodies. Biocompatibility testing may require GLP compliance.

Step 6: Consider Validity and Stability

Some countries require test reports issued within the past two or three years; older reports may not be accepted. Additionally, sterilization validation and aging test data must align with product shelf life. If product specifications change, reports may become invalid.

Data and Evidence

When considering reuse of test reports, companies should first inventory available materials. Typically reusable or referable materials include: physicochemical performance test reports, biocompatibility evaluation reports (e.g., cytotoxicity, sensitization, irritation or intracutaneous reactivity), microbiological validation reports (sterility, bacterial endotoxins, particulate contamination), ethylene oxide residue reports, and sterilization validation reports (e.g., EO, irradiation, or steam sterilization).

It is important to note that test reports are not isolated documents; regulators focus on the underlying evidence chain. Therefore, companies should also prepare corresponding quality system documents, including ISO 13485 certificates, process validation reports, raw material inspection records, stability test protocols and reports, and risk management documentation (ISO 14971).

If the target country is a GHWP member or adopts ICH/IMDRF harmonized frameworks, some test data may have mutual recognition basis, but technical documentation localization is still required. For example, test reports may need to be translated into the local official language, and translations often need notarization or confirmation by the authorized representative.

If the target country requires local testing and cannot directly use overseas reports, companies must arrange retesting with a qualified local laboratory or submit the original report to a recognized body for technical review and opinion. In such cases, companies should understand the laboratory's scope of accreditation, turnaround time, and costs in advance to avoid affecting the registration schedule.

In addition, labels and instructions for use are part of the registration dossier and must be consistent with test reports. Companies need to verify target country requirements for labels, instructions, language, and symbols, and re-issue packaging validation data if necessary. If label changes affect material contact area or usage method, biocompatibility conclusions may also be affected.

Common Mistakes

• Assuming that NMPA test reports can be used directly in all countries, ignoring standard differences and recognized body requirements.
• Only checking whether test items are complete, without verifying that the product model, specification, and structural composition in the report exactly match the product for registration.
• Not checking the issuance date of test reports, causing the report to exceed the target country's recognized validity period.
• Using laboratory reports without ISO 17025, GLP, or MDSAP accreditation marks, leading to direct rejection.
• Overlooking the role of the local agent, and not understanding that most regulators only accept local submission and communication.
• Ignoring localization of labels and instructions, resulting in incomplete dossiers even if test reports are qualified.
• Failing to plan for multi-country submissions, leading to duplicate preparation and deficiencies for each country.
• Neglecting post-market maintenance requirements, as changes and renewals require resubmission of relevant data.

Enterprise Preparation Checklist

• Clarify the target country, product classification, registration pathway, and whether the product falls under medical device regulation.
• Establish a product technical documentation library, organizing all existing test reports, raw data, validation protocols, and conclusions.
• Conduct a gap analysis against target country standards, listing items that require supplementary testing and the applicable reference standards.
• Verify the issuing laboratory's qualification for each report, and confirm with the target country if acceptance is unclear.
• Check report validity, sample model/specification, product name, and address information to ensure consistency with the intended registration version.
• Prepare quality system documents, such as ISO 13485 certificates, MDSAP certificates, or equivalent system certifications.
• Identify and contract a local agent or authorized representative, clearly defining responsibilities for submission, changes, renewal, and adverse event reporting.
• Complete localization of labels and instructions according to target country requirements, and update related validation records.
• Develop a post-market maintenance plan, including product change assessment, annual updates, vigilance, and recall obligations.
• For multi-country registration, consider identifying a reference country and baseline standards, outputting a reusable core technical document set, then performing lightweight localization per country.

AIMEILI's Perspective

The most common misjudgment is equating “same test items” with “valid test report,” while ignoring the strict limitations regulators place on laboratory qualifications, standard versions, and applicability to specific countries. Many companies submit new NMPA test reports for Southeast Asian registration, only to be required to retest because the issuing laboratory lacks target country recognition, severely impacting project timeline and budget.

We recommend conducting a “registration and testing gap assessment” early in the project, rather than directly proceeding to translation and submission. First clarify the target country's requirements for report format, issuing agency, and standard version, then decide which reports can be reused and which must be supplemented or localized.

Based on experience, data based on mature standards, such as physicochemical properties, microbial limits, and sterility tests, generally have high reuse value. However, biocompatibility, sterilization validation, and shelf-life aging data often require stricter review, and GLP requirements vary by country. Priority should be given to confirming their acceptability.

Furthermore, the local agent and certificate control rights must be addressed early. In many countries, the registration certificate is held by the local agent; changing agents can lead to suspension of registration or even re-application. Companies should clarify the agent's obligations regarding changes and cooperation in the agreement. Also, the information in the certificate must match that in test reports. Any address, name, or product composition change may trigger report updates, so a change assessment mechanism must be established.

For multi-country registration, we advocate a “one core data set, multi-country localized submission” strategy. Companies should build a core technical document set based on international standards (e.g., ISO, IEC, EN) and then have local regulatory consultants adjust formats and supplement differential data according to target country requirements. This approach reduces duplicate documentation risk and improves deficiency response efficiency. Test report reuse is not simple copying but a strategic transformation of the evidence chain and risk control.

Common Follow-up Questions

Can NMPA test reports be used directly for EU CE registration?

It depends on the standards underlying the report and the issuing laboratory. The EU MDR requires notified bodies to assess the adequacy of test reports, and testing laboratories generally need ISO 17025 accreditation or compliance with EU laboratory capability requirements. If the NMPA report is based on ISO standards and the laboratory holds the relevant accreditation, it can be used as part of the technical documentation. However, notified bodies may require additional or repeated testing, especially for clinical evaluation and biocompatibility.

Can the same test report be used for registration in multiple countries simultaneously?

In theory, yes, but the report must satisfy each country's requirements regarding issuing agency, validity, language, and standards. Companies should create a report comparison table to verify, item by item, the acceptance of test items and laboratory qualifications. For GHWP member countries, harmonization is higher, but Southeast Asia, the Middle East, and Latin America still have significant differences. When submitting a unified core report to multiple countries, include necessary explanatory notes on differences and supplementary test data.

What if the test report is issued by a domestic third-party laboratory and the target country does not recognize it?

If the target country does not recognize the domestic third-party laboratory, companies must choose a recognized overseas laboratory or use the ILAC-MRA mutual recognition mechanism to select a qualified laboratory for retesting. Alternatively, some countries allow the original report to be sent to a designated local body for technical review, and after review, it may be accepted as a basis for registration. We recommend communicating with the target country regulator or local agent early to clarify alternative pathways and avoid rejection.

Continue Reading

Related topics include grouping strategies for AI medical device multi-model overseas registration, allocation of authorized representative responsibilities for sterile consumables, common reasons for data corrections in sterile consumable registration applications, when to notify changes for sterile consumable registrations, risk management documentation requirements for home medical devices, and localization of labels and instructions for software medical devices.